Flexeril (Cyclobenzaprine) Use in First Trimester
Flexeril should be avoided during the first trimester of pregnancy unless absolutely necessary, as it is classified as FDA Pregnancy Category B with concerning emerging safety signals and no adequate human data to confirm safety.
FDA Classification and Official Guidance
The FDA drug label classifies cyclobenzaprine as Pregnancy Category B 111. While animal reproduction studies at doses up to 20 times the human dose showed no evidence of impaired fertility or fetal harm, there are no adequate and well-controlled studies in pregnant women. The label explicitly states: "Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed" 111.
Emerging Safety Concerns from Human Data
Recent research raises significant red flags that contradict the reassuring animal data:
Birth Defects Association
A large 2023 case-control study combining data from two major U.S. birth defects surveillance systems (33,615 cases, 13,110 controls) found elevated risks for multiple structural birth defects with periconceptional cyclobenzaprine exposure 2:
- Cleft palate: OR 4.79 (95% CI 1.71-13.44)
- Anorectal atresia/stenosis: OR 6.91 (95% CI 1.67-28.65)
- D-transposition of great arteries: OR 6.97 (95% CI 2.17-22.36)
- Coarctation of aorta: OR 5.58 (95% CI 1.88-16.58)
- Pulmonary valve stenosis: OR 4.55 (95% CI 1.10-18.87)
While exposure was rare (0.15% of cases, 0.07% of controls) and estimates are unadjusted, the consistency across multiple cardiac and orofacial defects is concerning 2.
Ductal Closure Risk
A 2014 case report documented persistent pulmonary hypertension and early ductal closure in a neonate whose mother used cyclobenzaprine during late pregnancy 3. The proposed mechanism involves cyclobenzaprine's inhibition of norepinephrine and serotonin reuptake, which can suppress prostaglandin and nitric oxide—key factors maintaining ductal patency 3.
Clinical Decision Framework
When cyclobenzaprine is being considered in first trimester:
Assess absolute necessity: Is this for acute muscle spasm that could be managed with safer alternatives?
Consider safer alternatives first:
If cyclobenzaprine exposure has already occurred: Counsel patient about the emerging but imprecise safety signals, offer detailed anatomic ultrasound and fetal echocardiography at 18-22 weeks
Document shared decision-making: If proceeding despite concerns, document discussion of unknown risks, lack of human safety data, and emerging signals
Key Caveats
- The birth defects study had very small numbers of exposed pregnancies and unadjusted estimates, making causality uncertain 2
- Cyclobenzaprine is structurally related to tricyclic antidepressants, which have their own pregnancy considerations 11
- The drug's mechanism (serotonin/norepinephrine reuptake inhibition) theoretically poses risks throughout pregnancy, not just first trimester 3
- No rheumatology or obstetric guidelines specifically address cyclobenzaprine in pregnancy—the EULAR guidelines focus on disease-modifying drugs and do not mention muscle relaxants 444
Bottom Line
Despite the FDA Category B designation based on animal data, emerging human evidence suggests potential teratogenic risks that warrant extreme caution. The risk-benefit calculation favors avoiding cyclobenzaprine in the first trimester unless no safer alternatives exist for a serious maternal condition. This represents a situation where the FDA label (based on older animal data) may not reflect current understanding from human observational studies.